Pharmaceutical compositions for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides methods for reducing Aβ deposition, Aβ neurotoxicity and microgliosis in an animal or human afflicted with a cerebral amyloidogenic disease, such as Alzheimer'"'"'s disease (AD), by administering therapeutically effective amounts of the (R)-enantiomer of the dihydropyridine compound nilvadipine, also known as (−)-nilvadipine, to the animal or human. Further provided are methods for reducing the risk of Aβ deposition, Aβ neurotoxicity and microgliosis in animals or humans suffering from traumatic brain injury by administering (−)-nilvadipine after the traumatic brain injury and continuing treatment for a prescribed period of time thereafter.
-
Citations
22 Claims
-
1-14. -14. (canceled)
-
15. A pharmaceutical composition comprising optically active nilvadipine and a pharmaceutically acceptable carrier, the pharmaceutical composition comprising an excess of (−
- )(R) nilvadipine relative to (+)(S) nilvadipine.
- View Dependent Claims (16, 17, 18, 19, 20, 21, 22)
Specification